Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy

Figure 4

Expanded/activated γδ T cells were manufactured as described in the text.

Flow cytometry from two separate donors shown from (a) unmanipulated and (b) P140KMGMT-transduced γδ T cells. For both panels (a) and (b) quadrant 2 (Q2) represents γδ T cells. As discussed in the text, the yield of γδ T cells was slightly lower than control due to loss of cells during the transduction procedure; however, purity of the final product was not affected as both products from a single donor show >90% purity of γδ T cells. (c and d) Cytotoxicity assays from two separate expansions (panel c and d, respectively) of unmodified γδ T cells (solid line) versus TMZ P140KMGMT transduced γδ T cells (dashed line) against the TMZ-resistant glioma cell line U87 were conducted to determine if genetic modification impairs γδ T cell function. Cytolytic activity of γδ T cells against U87 cells was nearly equivalent at all E:T ratios, verifying that P140KMGMT transduced γδ T cells function is equivalent to that of unmodified γδ T cells.

Figure 4